Andere Sprachen Fate Therapeutics, Inc.

Aktien

A1W50M

US31189P1021

FATE

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 26.04.2024			% 5 Tage	% 1. Jan.
3,8 ^USD	-1,81 %		-20,67 %	+1,60 %

22.04.	Fate Therapeutics, Inc. kündigt Präsentation von FT819 Proof-of-Concept-Daten für B-Zell-vermittelte Autoimmunkrankheiten auf der ASGCT-Jahrestagung an	CI
19.03.	Fate Therapeutics preist 100 Millionen Dollar Angebot, Privatplatzierung	MT

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Fate Therapeutics Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting	22.04.
Fate Therapeutics, Inc. Announces Presentation of FT819 Proof-of-Concept Data for B cell-mediated Autoimmune Diseases at ASGCT Annual Meeting	22.04.
Fate Therapeutics Reports New Employee Inducement Award under Nasdaq Listing Rule 5635(4)	03.04.
Fate Therapeutics to Present at 23rd Annual Needham Virtual Healthcare Conference	03.04.
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)	02.04.
Fate Therapeutics, Inc. announced that it has received $19.996366 million in funding from Redmile Group, LLC	21.03.
Fate Therapeutics Prices $100 Million Offering, Private Placement	19.03.
Fate Therapeutics Announces Pricing of $100 Million Underwritten Offering and Concurrent Private Placement	19.03.
Fate Therapeutics, Inc. announced that it expects to receive $19.996366 million in funding from Redmile Group, LLC	19.03.
Fate Therapeutics, Inc.(NasdaqGM:FATE) added to S&P Biotechnology Select Industry Index	18.03.
Fate Therapeutics Reports New Employee Inducement Award under Nasdaq Listing Rule 5635(4)	06.03.
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)	05.03.
Fate Therapeutics to Present at Upcoming March Investor Conferences	04.03.
Fate Therapeutics to Present at Upcoming March Investor Conferences	01.03.
Fate Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	26.02.
Fate Therapeutics: Q4 Earnings Snapshot	26.02.
Earnings Flash (FATE) FATE THERAPEUTICS Posts Q4 Revenue $1.7M, vs. Street Est of $1.5M	26.02.
Fate Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates	26.02.
Fate Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	26.02.
Fate Therapeutics to Webcast Conference Call Reporting Fourth Quarter and Full Year 2023 Financial Results	15.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Fate Therapeutics, Inc.

Aktien

A1W50M

US31189P1021

FATE

Andere Sprachen

Filter